Search results for "pancreatic neoplasm"

showing 10 items of 192 documents

The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases.

2003

Apoptosis induced by DNA-damaging agents or radiation mainly proceeds through death receptor-independent caspase activation. The release of mitochondrial apoptogenic proteins, such as cytochrome c, into the cytoplasm leading to Apaf1-dependent activation of caspase-9 is a key event in this pathway. The permeability of the mitochondrial outer membrane is regulated by the various pro- and antiapoptotic Bcl-2 family proteins, and it is thought that DNA damage triggers apoptosis through the downregulation of antiapoptotic Bcl-2. Using murine embryonic fibroblasts (MEF) deficient and proficient in Apaf1, we show that DNA-damaging agents and radiation lead to a decline in Bcl-2 protein only in wt…

Cancer ResearchDNA damageCell TransplantationUltraviolet RaysTransplantation HeterologousApoptosisMice SCIDAdenocarcinomamedicine.disease_causeAdenoviridaeAmino Acid Chloromethyl KetonesMiceDownregulation and upregulationGeneticsmedicineTumor Cells CulturedAnimalsHumansAPAF1Enzyme InhibitorsMolecular BiologyCaspaseEtoposidebiologyDose-Response Relationship DrugCytochrome cProteinsDose-Response Relationship RadiationFibroblastsMolecular biologyCaspase InhibitorsCell biologyEnzyme ActivationPancreatic NeoplasmsApoptotic Protease-Activating Factor 1Proto-Oncogene Proteins c-bcl-2ApoptosisCytoplasmCaspasesbiology.proteinDactinomycinCarcinogenesisGene DeletionDNA DamageOncogene
researchProduct

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

2021

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer patients present with locally advanced or metastatic disease characterized by inherent resistance to chemotherapy. These features pose a series of therapeutic challenges and new targets are urgently needed. Glycogen synthase kinase 3 beta (GSK3β) is a conserved serine/threonine kinase, which regulates key cellular processes including cell proliferation, DNA repair, cell cycle progression, signaling and metabolic pathways. GSK3β is implicated in non-malignant and malignant diseases including inflammation, neurodegenerative …

Cancer ResearchDNA repairDruggabilityDiseaseMalignancyPancreatic cancerHumansMedicinePharmacology (medical)GSK3BCell ProliferationPharmacologyGlycogen Synthase Kinase 3 betabusiness.industryKinaseGSK3βCancerTumor chromatin profilingOncogenesPancreatic cancermedicine.diseaseAnticancer drug combinationsPancreatic NeoplasmsInfectious DiseasesOncologyDrug Resistance NeoplasmCancer researchbusinessChemoresistanceDrug Resistance Updates
researchProduct

Cytoskeletal differences between human neuroendocrine tumors: A cytoskeletal protein of molecular weight 46,000 distinguishes cutaneous from pulmonar…

1985

The cytoskeletons of various human neuroendocrine (NE) tumors were analyzed immunohistochemically using antibodies against intermediate-filament (IF) proteins as well as by two-dimensional gel electrophoresis of proteins from microdissected tissue samples. All of the tumors studied were found to contain cytokeratin filaments and are therefore referred to as 'NE tumors of the epithelial type'. In addition, neurofilaments were found in most cutaneous and some pulmonary NE tumors, as well as in medullary carcinomas of the thyroid and in pancreatic islet cell tumors. The neurofilament staining was frequently concentrated in cytoplasmic IF aggregates. Gel-electrophoretic analyses showed that all…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsSkin NeoplasmsNeurofilamentCarcinoid TumorHistogenesisBiologyNeuroendocrine tumorsDiagnosis DifferentialCytokeratinIntestinal NeoplasmsKeratinmedicineCarcinomaHumansThyroid NeoplasmsCarcinoma Small CellMolecular Biologychemistry.chemical_classificationThyroidCell Biologymedicine.diseaseNeoplasm ProteinsMolecular WeightPancreatic NeoplasmsCytoskeletal Proteinsmedicine.anatomical_structurechemistryImmunologyPancreasDevelopmental BiologyDifferentiation
researchProduct

De novo expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in pancreas cancer.

1993

We examined the expression of intercellular--adhesion molecule-I (ICAM-I, CD54) in 6 surgically removed pancreatic tumors and 8 pancreatic tumor cell lines. Immunohistochemistry revealed a varying percentage of ICAM-I-positive pancreas tumor cells, while normal pancreatic tissue (except for slight reactivity of endothelial cells) was not stained. The presence of the ICAM-I molecule on the cell surface and the expression of ICAM-I mRNA were investigated for 8 different pancreatic tumor cell lines. Three of these (Capan-I, Capan-2, QGP-I) expressed ICAM-I constitutively. In 4 of the ICAM-I-negative pancreas cancer cell lines, it was possible to induce a remarkable expression of ICAM-I by incu…

Cancer ResearchPathologymedicine.medical_specialtyPancreatic diseaseCellMolecular Sequence DataBiologyProinflammatory cytokineImmunoenzyme TechniquesPancreatic tumorAntigens CDmedicineTumor Cells CulturedHumansRNA MessengerRNA NeoplasmBase SequenceCell adhesion moleculeCancermedicine.diseaseIntercellular Adhesion Molecule-1Molecular biologyPancreatic Neoplasmsmedicine.anatomical_structureOncologyCell culturePancreasCell Adhesion MoleculesInternational journal of cancer
researchProduct

2-Triazenoazaindoles: Α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells

2012

Pancreatic cancer is a complex malignancy arising from the accumulation of genetic and epigenetic defects in the affected cells. Standard chemotherapy for patients with advanced disease shows only modest effects and is associated with considerable toxicity. Overexpression or aberrant activation of members of the epidermal growth factor receptor tyrosine kinase family, which includes EGFR and HER-2, occurs frequently and is associated with multiple drug resistance and decreased patient survival. In this study, we have investigated the therapeutic potential of AS104, a novel compound of the triazene class, with potential inhibitory effects on EGFR. We found that treatment of cells with AS104 …

Cancer ResearchProgrammed cell deathmedicine.medical_specialtyIndolesReceptor ErbB-2EGFRCellpancreatic cancer2-triazenoazaindoles pancreatic cancer cell death EGFR HER-2Down-RegulationApoptosisCell Growth ProcessesBiologyReceptor tyrosine kinasePancreatic cancerInternal medicineCell Line TumormedicineAutophagyHumansMolecular Targeted TherapyOncogeneCell growthCancerArticlesCell cyclemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaErbB ReceptorsPancreatic Neoplasmsmedicine.anatomical_structureEndocrinologycell deathOncologyHER-2Cancer researchbiology.protein2-triazenoazaindolesTriazenesCarcinoma Pancreatic Ductal
researchProduct

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening…

Cancer Researchmedicine.medical_specialtyConsensusReviewDiseaseMedical OncologySystemic therapyNOconsensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Consensus; Humans; Medical Oncology; Diabetes Mellitus; Pancreatic Neoplasms; PhysiciansDiabetes mellitusPancreatic cancerPhysiciansmedicineDiabetes MellitusHumansFamily historyRisk factorLS4_3Intensive care medicinediabetes pancreatic carcinoma early diagnosis consensus hyperglycaemiadiabetespancreatic carcinomabusiness.industryPublic healthmedicine.diseasePancreatic NeoplasmsOncologyPosition paperbusinesshyperglycaemiaearly diagnosis
researchProduct

GADD45α is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability

2005

Pancreatic ductal adenocarcinoma is one of the most common causes of cancer death in the western civilization. Recently, NF-kappaB has been shown to be activated in pancreatic ductal adenocarcinoma through constitutive activation of IkappaB kinase (IKK). Inhibition of NF-kappaB by a super-inhibitor of NF-kappaB--delta-N-IkappaBalpha--resulted in impaired proliferation and induction of apoptosis, suggesting an important role of NF-kappaB in pancreatic tumorigenesis. Downstream target genes of IkappaBalpha have not been elucidated in pancreatic ductal adenocarcinoma in detail. Using expression profiling by cDNA array analysis of pancreatic ductal adenocarcinoma cell lines stably transfected w…

Cancer Researchmedicine.medical_specialtyPancreatic diseaseCell SurvivalDown-RegulationCell Cycle ProteinsIκB kinaseAdenocarcinomaBiologymedicine.disease_causeDownregulation and upregulationPancreatic cancerInternal medicinemedicineHumansCell ProliferationCell growthGene Expression ProfilingNF-kappa BNuclear Proteinsmedicine.diseaseI-kappa B KinasePancreatic NeoplasmsEndocrinologyOncologyApoptosisCancer researchRNA InterferenceCA19-9CarcinogenesisCarcinoma Pancreatic DuctalInternational Journal of Cancer
researchProduct

ERCP and MRCP--when and why.

2002

Since the introduction of endoscopic retrograde cholangiopancreatography (ERCP) in the 1970s, gastroenterologists have a wide spectrum of diagnostic and therapeutic options in the biliopancreatic ductal system at their disposal. With its arrival in the 1990s, magnetic resonance cholangiopancreatography (MRCP) developed as a potent diagnostic tool in biliopancreatic pathology. Currently, MRCP is widely replacing diagnostic ERCP and thereby avoiding complications related to endoscopic technique.We summarize evidence-based data and demonstrate indications and differential indications for MRCP and ERCP in pancreatic disease. Complications related to the procedures and possible medical preventio…

Cholangiopancreatography Endoscopic Retrogrademedicine.medical_specialtyMagnetic resonance cholangiopancreatographyEndoscopic retrograde cholangiopancreatographyPancreatic diseasemedicine.diagnostic_testbusiness.industryGastroenterologyPancreatic DiseasesInterventional radiologymedicine.diseaseMagnetic Resonance ImagingPancreatic NeoplasmsmedicinePancreatitisHumansInterventional endoscopyRadiologybusinessBest practiceresearch. Clinical gastroenterology
researchProduct

Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical …

2022

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology…

ConsensusSettore MED/06 - Oncologia MedicaGEP-NET progressionMetabolic disordersHematologyMedical OncologyMetabolic syndromeNOGEP-NET survivalPancreatic NeoplasmsNeuroendocrine Tumorsgastroenteropancreatic neuroendocrine tumors; gep-net progression; gep-net survival; metabolic disorders; metabolic syndrome; consensus; humans; medical oncology; diabetes mellitus; type 2; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; stomach neoplasmsOncologyGEP-NET progression; GEP-NET survival; Gastroenteropancreatic neuroendocrine tumors; Metabolic disorders; Metabolic syndromeDiabetes Mellitus Type 2Stomach NeoplasmsIntestinal NeoplasmsDiabetes MellitusHumansLS4_3Gastroenteropancreatic neuroendocrine tumorsType 2
researchProduct

FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells

2019

Background/aim Cytokine-induced killer (CIK) cells are ex vivo expanded major histocompatibility complex (MHC)-unrestricted cytotoxic cells with promising effects against a variety of cancer types. Regulatory T-cells (T-reg) have been shown to reduce the effectiveness of CIK cells against tumor cells. Peptide P60 has been shown to inhibit the immunosuppressive functions of T-regs. This study aimed at examining the effect of p60 on CIK cells efficacy against renal and pancreatic cancer cells. Materials and methods The effect of P60 on CIK cytotoxicity was examined using flow cytometry, WST-8-based cell viability assay and interferon γ (IFNγ) ELISA. Results P60 treatment resulted in a signifi…

Cytotoxicity ImmunologicCancer ResearchFOXP3Cell SurvivalImmunotherapy.KidneyMajor histocompatibility complexT-Lymphocytes RegulatoryInterferon-gamma03 medical and health sciencesCytokine-Induced Killer Cells0302 clinical medicineCytokine-induced killer (CIK) cellCell Line TumorPancreatic cancermedicineHumansCytotoxic T cellViability assayCytotoxicityPancreasCancerCytokine-induced killer cellbiologyChemistryFOXP3Forkhead Transcription FactorsGeneral Medicinemedicine.diseaseCoculture TechniquesKidney NeoplasmsPancreatic NeoplasmsOncologyCell culture030220 oncology & carcinogenesisAdoptive cell transferCancer researchbiology.proteinCytokinesPeptidesAnticancer Research
researchProduct